HC Wainwright Reaffirms “Neutral” Rating for Bolt Biotherapeutics (NASDAQ:BOLT)

Posted by Lars Charter on Nov 13th, 2024

Bolt Biotherapeutics (NASDAQ:BOLT – Get Free Report)‘s stock had its “neutral” rating restated by analysts at HC Wainwright in a report issued on Wednesday,Benzinga reports.

Bolt Biotherapeutics Stock Performance

Shares of Bolt Biotherapeutics stock opened at $0.64 on Wednesday. Bolt Biotherapeutics has a fifty-two week low of $0.55 and a fifty-two week high of $1.56. The company has a debt-to-equity ratio of 0.19, a current ratio of 4.28 and a quick ratio of 4.28. The firm has a market capitalization of $24.56 million, a P/E ratio of -0.37 and a beta of 0.92. The company’s 50 day moving average price is $0.64 and its two-hundred day moving average price is $0.74.

Bolt Biotherapeutics (NASDAQ:BOLT – Get Free Report) last issued its earnings results on Tuesday, August 13th. The company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.08). Bolt Biotherapeutics had a negative net margin of 592.57% and a negative return on equity of 61.40%. The company had revenue of $1.28 million during the quarter, compared to analyst estimates of $1.19 million. On average, equities analysts forecast that Bolt Biotherapeutics will post -1.52 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Bolt Biotherapeutics

A hedge fund recently bought a new stake in Bolt Biotherapeutics stock. Assenagon Asset Management S.A. bought a new position in shares of Bolt Biotherapeutics, Inc. (NASDAQ:BOLT – Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 34,488 shares of the company’s stock, valued at approximately $26,000. Assenagon Asset Management S.A. owned about 0.09% of Bolt Biotherapeutics as of its most recent SEC filing. Institutional investors own 86.70% of the company’s stock.

About Bolt Biotherapeutics

(Get Free Report)

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.